- Current report filing (8-K)
April 17 2012 - 1:59PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of
1934
Date of Report (date of earliest event reported): April 17, 2012
K-V PHARMACEUTICAL COMPANY
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
1-9601
|
|
43-0618919
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
2280 Schuetz Road St. Louis, MO
|
|
|
|
63146
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
(314) 645-6600
(Registrants telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act.
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
On
April 12, 2012, K-V Pharmaceutical Company (the Company) issued a press release announcing that Gregory Divis, President and Chief Executive Officer of the Company, and Thomas McHugh, Chief Financial Officer of the Company, are
scheduled to present at the Imperial Capital 2012 Healthcare Investor Forum on Tuesday, April 17, 2012 at 2:00 p.m. EDT. Attached is a copy of the materials to be presented.
Item 9.01
|
Financial Statements and Exhibits.
|
The following information is filed as part of this report:
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Materials to be presented at the April 17, 2012 Imperial Capital 2012 Healthcare Investor Forum.
|
The Registrant will post this Form 8-K on its Internet website at www.kvpharmaceutical.com. References to the
Registrants website address are included in this Form 8-K only as inactive textual references and the Registrant does not intend them to be active links to its website. Information contained on the Registrants website does not constitute
part of this Form 8-K.
* *
*
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 17, 2012
|
|
|
K-V PHARMACEUTICAL COMPANY
|
|
|
By:
|
|
/s/ Patrick J. Christmas
|
|
|
Patrick J. Christmas
|
|
|
VP, General Counsel and Secretary
|
K V Pharma (NYSE:KV.A)
Historical Stock Chart
From Sep 2024 to Oct 2024
K V Pharma (NYSE:KV.A)
Historical Stock Chart
From Oct 2023 to Oct 2024